InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,292.63
(
2.05%
)
US TECH 100
17,804.80
(
2.24%
)
Dow Jones
39,291.30
(
1.52%
)
Brent Oil
76.79
(
-0.48%
)
Bitcoin
56,471.26
(
4.59%
)
Post# of 252792
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 120220
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: pcrutch post# 127356

Monday, 09/26/2011 3:02:46 PM

Monday, September 26, 2011 3:02:46 PM

Post# of 252792

Can NVS extend the patent life of Gleevec via this indication (PAH)?

What NVS can do is obtain three years of Hatch-Waxman marketing exclusivity for the new indication, but this doesn’t help ARIA.

Note that the imatinib dose for PAH is likely to be 200mg, which is not one of approved dosage strengths for Gleevec. This is almost certainly intentional.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up